AHA reiterates support for most-favored nation drug price rule’s withdrawal
The AHA today restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule. In January, the AHA questioned the proposal’s legality and structure, while expressing deep concerns for the extent to which patients would be negatively impacted by the policy.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…
Headline
AHA Board Chair Marc Boom, M.D., took the stage July 13 to introduce AHA award winners and a town hall discussion on navigating the 2026 political…
Perspective
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The AHA provided a statement June 30 to the House Ways and Means Committee in advance of a markup July 1 where the committee will consider legislation that…
Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…